PureTech Health plc

Transaction in Own Shares • Nov 15, 2023

National Storage Mechanism | Additional information

RNS Number : 4530T

PureTech Health PLC

15 November 2023

15 November 2023

PureTech Health plc

Transaction in Own Shares

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

Date of purchase:	14 November 2023
Number of ordinary shares purchased:	2,116
Highest price paid per share:	174.00p
Lowest price paid per share:	173.20p
Volume weighted average price paid per share:	173.39p

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,285,859 ordinary shares in treasury and has 273,182,300 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,182,300 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

Transaction Date	Transaction Time	Volume	Price (GBp)	Platform	Transaction Reference Number
14/11/2023	08:09:59	40	173.2	XLON	00378182799TRLO0.1.1
14/11/2023	08:10:09	482	173.2	CHIX	00378182809TRLO0.1.1
14/11/2023	08:10:42	462	173.2	XLON	00378182867TRLO0.1.1
14/11/2023	08:10:42	612	173.2	BATE	00378182868TRLO0.1.1
14/11/2023	08:10:42	20	173.2	CHIX	00378182869TRLO0.1.1
14/11/2023	10:17:59	500	174	CHIX	00378196528TRLO0.1.1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSFLFSDLSLSLIV